Daily Stock Analysis, ECYT, Endocyte Inc, priceseries

Endocyte Inc. Daily Stock Analysis
Stock Information
Open
0.00
Close
0.00
High
0.00
Low
0.00
Previous Close
0.00
Daily Price Gain
0.00
YTD High
0.00
YTD High Date
Wrong Month 0, 0
YTD Low
0.00
YTD Low Date
Wrong Month 0, 0
YTD Price Change
0.00
YTD Gain
-nan%
52 Week High
0.00
52 Week High Date
Wrong Month 0, 0
52 Week Low
0.00
52 Week Low Date
Wrong Month 0, 0
52 Week Price Change
0.00
52 Week Gain
-nan%
Company Information
Stock Symbol
ECYT
Exchange
NasdaqGS
Company URL
http://www.endocyte.com
Company Phone
7654637175
CEO
Michael A. Sherman
Headquarters
Indiana
Business Address
3000 KENT AVE STE A1-100, WEST LAFAYETTE, IN 47906
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001235007
About

Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.

Description

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.